Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Enliven Therapeutics Inc (Enliven Therapeutics) is a clinical-stage biopharmaceutical company. It focuses on the discovery and development of small molecule therapeutics aimed at improving patient outcomes in oncology. The company's activities carry out developing kinase inhibitors that enhance efficacy through better selectivity and combinability, combat resistance, address brain metastases, and improve safety and patient convenience. Enliven Therapeutics' pipeline products include ELVN-001, a BCR-ABL kinase inhibitor for chronic myeloid leukemia, and ELVN-002, a HER2 inhibitor for various solid tumors. The company's products are designed for cancer patients, particularly those with unmet needs in precision oncology, and are applicable across multiple cancer types. Enliven Therapeutics is headquartered in Boulder, Colorado, the US.
Headquarters
United States of America
Address
6200 Lookout Road, Boulder, Colorado, 80301
Website
www.enliventherapeutics.com
Telephone
1 720 6478519
No of Employees
67
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ELVN (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-16.5%
(2024 vs 2023)
Market Cap*
$4.4B
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline: |
| ELVN- 001: Chronic Myeloid Leukemia (CML) |
| ELVN- 002: Non-Small Cell Lung Cancer (NSCLC) and Solid Tumors |
Competitor Comparison
| Key Parameters | Enliven Therapeutics Inc | Geron Corp | ImmunityBio Inc | Crescent Biopharma Inc | Precigen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Boulder | Foster City | San Diego | Waltham | Germantown |
| State/Province | Colorado | California | California | Massachusetts | Maryland |
| No. of Employees | 67 | 258 | 691 | 44 | 160 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard Fair | Chief Executive Officer; President; Director | Executive Board | 2025 | 57 |
| Benjamin Hohl | Chief Financial Officer; Head - Corporate Development | Senior Management | 2023 | 37 |
| Helen Collins, M.D. | Chief Medical Officer | Senior Management | 2023 | 63 |
| Jake Bauer | Director | Non Executive Board | 2023 | 47 |
| Lori Kunkel, M.D | Director | Non Executive Board | 2024 | 68 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer